Global Biopharmaceutical Industry Commitment
to Address Coronavirus Public Health Crisis

As part of the global health community, biopharmaceutical companies are committed to playing the greatest possible role in the rapid, global response to COVID-19. Learn about our commitments and how we're leading the way in developing diagnostics, treatments and vaccines for COVID-19.

Back to List

Pfizer Inc

pfizer.com

At Pfizer, our business and social mission are one in the same – improve health. We have made significant and far-reaching contributions to improving health around the world for more than 160 years.

Our medicines, vaccines and programs reach millions of people annually. We direct our resources – our medicines and vaccines, our funding and our colleagues’ expertise – where we can have the greatest global health impact. Through our global health programs and partnerships, Pfizer supports initiatives that increase access to life-saving products while also strengthening overall health systems to deliver for the most vulnerable patients in need.

COLLABORATIONS

SHOWING 5 of 25 COLLABORATIONS

See All

Access Accelerated Initiative

Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...

Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., International Federation of Pharmaceutical Manufacturers & Associations, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Dainippon, Takeda Pharmaceutical Company Limited, UCB
 
Read More

SHOWING 5 of 25 COLLABORATIONS

See All